{"id":"linaprazan-glurate-high-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unlike proton pump inhibitors (PPIs) that irreversibly bind the H+/K+-ATPase, linaprazan competitively blocks potassium binding to the pump, allowing for faster onset and offset of acid suppression. This mechanism may provide more consistent 24-hour pH control and potentially faster healing of acid-related lesions. The glurate salt formulation is designed to improve bioavailability and tolerability.","oneSentence":"Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:03.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Acid-related disorders"}]},"trialDetails":[{"nctId":"NCT07313774","phase":"PHASE3","title":"A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)","status":"NOT_YET_RECRUITING","sponsor":"Cinclus Pharma Holding AB","startDate":"2026-03","conditions":"GERD (Gastroesophageal Reflux Disease)","enrollment":1050}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Linaprazan glurate - High dose","genericName":"Linaprazan glurate - High dose","companyName":"Cinclus Pharma Holding AB","companyId":"cinclus-pharma-holding-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Acid-related disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}